Profile data is unavailable for this security.
About the company
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
- Revenue in USD (TTM)0.00
- Net income in USD-6.26m
- Incorporated2018
- Employees4.00
- LocationOKYO Pharma LtdFloor 4, 14/15 Conduit StLONDON W1S 2XJUnited KingdomGBR
- Phone+44 207 495 2379
- Websitehttps://okyopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janel Corp | 212.13m | 5.02m | 53.39m | 353.00 | 10.80 | 2.26 | 6.04 | 0.2517 | 4.17 | 4.17 | 175.99 | 19.89 | 1.48 | 32.91 | 3.83 | 600,929.20 | 3.97 | 1.76 | 13.95 | 5.33 | 32.04 | 26.69 | 2.69 | 0.9608 | 0.7095 | 3.62 | 0.5020 | 0.00 | 13.24 | 20.27 | 2,155.61 | -- | -14.58 | -- |
| ImmuCell Corp | 27.77m | 2.32m | 56.45m | 70.00 | 24.11 | 1.89 | 11.24 | 2.03 | 0.2588 | 0.2588 | 3.09 | 3.29 | 0.6159 | 1.90 | 11.42 | 402,453.60 | 5.15 | -5.35 | 5.69 | -5.77 | 40.93 | 36.02 | 8.37 | -11.87 | 1.76 | 6.47 | 0.2415 | -- | 51.64 | 14.06 | 62.65 | -- | -19.66 | -- |
| Cumberland Pharmaceuticals, Inc. | 41.28m | -3.33m | 57.58m | 91.00 | -- | 2.20 | 45.63 | 1.39 | -0.2331 | -0.2331 | 2.79 | 1.75 | 0.5788 | 1.72 | 3.80 | 453,608.30 | -4.68 | -6.88 | -7.60 | -9.65 | 84.49 | 80.74 | -8.09 | -15.89 | 1.11 | -28.41 | 0.1688 | -- | -4.26 | 1.95 | -3.19 | -- | -29.32 | -- |
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 58.85m | 4.00 | -- | 0.9651 | -- | 7.95 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| Rafael Holdings Inc | 1.03m | -31.33m | 61.60m | 21.00 | -- | 0.7318 | -- | 59.86 | -0.8471 | -0.8471 | 0.0284 | 1.63 | 0.0107 | -- | 3.35 | 49,000.00 | -32.33 | -45.03 | -37.62 | -51.75 | 89.70 | -- | -3,034.89 | -8,772.74 | 3.98 | -- | 0.0074 | -- | 43.96 | -28.51 | 11.30 | -- | -47.65 | -- |
| LifeVantage Corp | 210.05m | 7.86m | 63.20m | 232.00 | 8.24 | 1.91 | 5.87 | 0.3009 | 0.5998 | 0.5998 | 16.16 | 2.58 | 3.24 | 2.45 | 96.73 | 905,370.70 | 12.12 | 9.17 | 18.91 | 14.08 | 78.75 | 80.73 | 3.74 | 2.93 | 1.03 | -- | 0.00 | 35.06 | 14.17 | -0.3794 | 233.84 | -3.22 | -12.55 | -- |
| MindWalk Holdings Corp | 14.97m | -22.73m | 64.43m | 102.00 | -- | 4.91 | -- | 4.30 | -0.6314 | -0.6131 | 0.3511 | 0.2813 | 0.4745 | 6.67 | 4.50 | -- | -72.01 | -32.32 | -90.53 | -36.45 | 58.50 | 55.79 | -151.78 | -100.97 | 4.09 | -23.68 | 0.17 | -- | 0.0082 | 11.77 | -11.25 | -- | 10.37 | -- |
| Scilex Holding Co | 40.36m | -375.84m | 68.52m | 30.00 | -- | -- | -- | 1.70 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 69.44m | 171.00 | -- | 0.3467 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| Nasus Pharma Ltd | 0.00 | -1.19m | 69.79m | -- | -- | -- | -- | -- | -0.1319 | -0.1383 | 0.00 | -0.4762 | 0.00 | -- | -- | -- | -373.32 | -- | -- | -- | -- | -- | -- | -- | -- | -2.51 | -- | -- | -- | -- | -54.23 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 2.83m | -7.95m | 70.54m | 14.00 | -- | -- | -- | 24.92 | -1.58 | 0.5377 | 0.555 | 0.2718 | 0.7686 | -- | 5.28 | 202,142.90 | -215.92 | -61.58 | -404.37 | -83.79 | 54.56 | 59.49 | -280.92 | -77.39 | -- | -91.56 | 0.0836 | -- | -33.58 | 8.19 | 48.52 | -- | -20.59 | -- |
| OKYO Pharma Ltd | 0.00 | -6.26m | 70.97m | 4.00 | -- | -- | -- | -- | -0.1543 | -0.1543 | 0.00 | -0.1205 | 0.00 | -- | -- | 0.00 | -123.47 | -248.30 | -- | -- | -- | -- | -- | -- | -- | -30.61 | -- | -- | -- | -- | 72.03 | -- | -- | -- |
| Assertio Holdings Inc | 137.35m | -28.92m | 77.32m | 58.00 | -- | 0.7308 | 35.04 | 0.5630 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Polypid Ltd | 0.00 | -34.17m | 80.28m | 57.00 | -- | 7.32 | -- | -- | -2.26 | -2.26 | 0.00 | 0.6028 | 0.00 | -- | -- | -- | -143.79 | -105.84 | -252.10 | -143.44 | -- | -- | -- | -- | 1.82 | -27.54 | 0.0826 | -- | -- | -- | -17.73 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 30.83m | -26.01m | 88.10m | 71.00 | -- | -- | -- | 2.86 | -3.44 | -3.44 | 3.50 | -1.80 | 0.8352 | 1.09 | 8.75 | 434,211.30 | -70.48 | -71.91 | -217.79 | -111.91 | 91.36 | -- | -84.38 | -729.00 | 1.18 | -1.70 | 1.94 | -- | 47.66 | -- | -14.31 | -- | -47.58 | -- |
